Cryoport, Inc.
- Open
- 15.79
- Day high
- 16.17
- Day low
- 15.60
- Prev close
- 15.72
- Volume
- 534K
- Mkt cap
- $792M
- P/E (TTM)
- 11.0
- EPS (TTM)
- $1.47
- P/B
- 1.6
- P/S
- 4.3
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$3.6M over the last 3 months (0 open-market buys, 4 sales)
- 🏛Institutions mixed (13F)
Cryoport, Inc. (CYRX) is a Industrials company listed on NASDAQ. The stock is up 104% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 4 sales (SEC Form 4).
Cryoport, Inc. (CYRX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 5 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
CYRX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-0.20 | $-0.23 | -15.0% | $48M | +6.5% |
| Mar 3, 2026 | $-0.19 | $-0.21 | -10.5% | $45M | +1.8% |
| May 7, 2025 | $-0.23 | $-0.22 | +4.3% | $41M | -3.3% |
| Mar 4, 2025 | $-0.33 | $-0.42 | -27.3% | $60M | +1.2% |
| Nov 7, 2024 | $-0.29 | $-0.02 | +93.1% | $57M | -3.6% |
| Mar 12, 2024 | $-0.32 | $-0.51 | -59.4% | $57M | -2.0% |
| May 4, 2023 | $-0.19 | $-0.16 | +15.8% | $63M | +1.1% |
| Feb 23, 2023 | $-0.19 | $-0.24 | -26.3% | $60M | +3.6% |
| Nov 3, 2022 | $-0.14 | $-0.15 | -7.1% | $60M | -13.6% |
| Aug 4, 2022 | $-0.15 | $-0.17 | -13.3% | $64M | -0.7% |
| May 5, 2022 | $-0.20 | $-0.31 | -55.0% | $52M | +0.1% |
| Feb 24, 2022 | $-0.15 | $-1.32 | -780.0% | $56M | -2.2% |
CYRX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 12, 2026 | ZECCHINI EDWARD Jofficer: Chief Digital and Tech Officer | Sell | 1,400 | $15.23 |
| Jun 12, 2026 | ZECCHINI EDWARD Jofficer: Chief Digital and Tech Officer | Option | 33,600 | $4.80 |
| Jun 12, 2026 | ZECCHINI EDWARD Jofficer: Chief Digital and Tech Officer | Sell | 33,600 | $14.47 |
| Jun 12, 2026 | ZECCHINI EDWARD Jofficer: Chief Digital and Tech Officer | Option | 1,400 | $4.80 |
| Jun 9, 2026 | BADDOUR LINDAdirector | Grant | 16,077 | $15.70 |
| Jun 9, 2026 | BADDOUR LINDAdirector | Grant | 10,350 | — |
| Jun 8, 2026 | HANCOCK DANIEL Mdirector | Grant | 10,350 | — |
| Jun 8, 2026 | Hariri Robert Jdirector | Grant | 10,350 | — |
| Jun 8, 2026 | STEFANOVICH ROBERTofficer: Chief Financial Officer | Sell | 169,427 | $16.27 |
| Jun 8, 2026 | Mandalam Ramkumardirector | Sell | 23,214 | $15.44 |
| Jun 8, 2026 | Hariri Robert Jdirector | Grant | 16,077 | $15.70 |
| Jun 8, 2026 | Mandalam Ramkumardirector | Grant | 10,350 | — |
| Jun 8, 2026 | HANCOCK DANIEL Mdirector | Grant | 16,077 | $15.70 |
| Jun 8, 2026 | Mandalam Ramkumardirector | Grant | 16,077 | $15.70 |
| Apr 23, 2026 | SHELTON JERRELLdirector, officer: President, CEO | Option | 104,007 | $1.87 |
Source: CYRX SEC Form 4 filings, latest Jun 12, 2026. For informational purposes only — not investment advice.
See the full CYRX insider & 13F page →Cryoport, Inc. company profile
Overview
Cryoport, Inc. (NASDAQ:CYRX) is a Tennessee-based life sciences services company founded in 1999 that specializes in temperature-controlled logistics solutions for the biotechnology and pharmaceutical industries. The company went public in 2005 and has evolved from a niche cryogenic shipping provider into a comprehensive logistics platform serving the rapidly growing cell and gene therapy market. Today, Cryoport operates globally across the Americas, Europe, the Middle East, Africa, and Asia Pacific, supporting over 675 clinical trials and 14 commercial therapies through its integrated suite of logistics services and cryogenic systems.
Business
Cryoport operates in the specialized field of temperature-controlled logistics for life sciences, focusing primarily on the transportation and storage of biological materials that require extremely cold temperatures to maintain their viability. The company serves three main market segments within the life sciences industry. The core business revolves around cell and gene therapy logistics, which represents the fastest-growing segment. Cell and gene therapies are revolutionary medical treatments that use living cells or genetic material to treat diseases, but these biological products are extremely sensitive to temperature variations and require specialized handling throughout the supply chain. Cryoport's services ensure these life-saving therapies maintain their integrity from manufacturing facilities to patients worldwide. The company's primary offering is CryoPort Express Shippers - specialized containers that maintain ultra-low temperatures (often below -150°C) during transport. These shippers are paired with the CryoPortal, a cloud-based logistics management platform that provides real-time tracking, monitoring, and documentation throughout the shipping process. The SmartPak Condition Monitoring System continuously collects data on temperature, location, and other environmental factors to ensure regulatory compliance and product integrity. Beyond shipping, Cryoport provides BioStorage and BioServices, which includes long-term cryogenic storage of biological specimens, sample management, and laboratory services. This segment has shown strong growth, increasing 45% year-over-year in recent periods. The company also operates MVE Biological Solutions, which manufactures and sells cryogenic freezer systems and vacuum-insulated dewars used by research institutions and biotechnology companies for storing biological materials. However, this segment has faced challenges, particularly in the Chinese market which previously represented a significant portion of revenues. Additionally, Cryoport has been developing IntegriCell, a platform designed to standardize the collection and processing of apheresis (a procedure to collect specific blood components), which is critical for certain cell therapies. This represents the company's expansion into upstream manufacturing support services. Revenue distribution shows services comprising approximately 62% of total revenue, with the remainder from equipment sales. The commercial cell and gene therapy segment has been the primary growth driver, expanding 33% year-over-year as more experimental therapies receive regulatory approval and enter commercial distribution.
Competitive moat
Cryoport's competitive moat is moderately strong but faces potential challenges as the market matures. The company's primary moat stems from its specialized expertise and regulatory compliance in handling extremely sensitive biological materials. The cell and gene therapy logistics market requires deep technical knowledge, validated processes, and extensive regulatory documentation - capabilities that take years to develop and prove to risk-averse pharmaceutical customers. The company benefits from high switching costs once integrated into a customer's supply chain. Pharmaceutical companies invest significant time and resources in validating logistics providers, and changing providers requires extensive revalidation studies that can delay critical clinical trials or commercial launches. This creates substantial customer stickiness, particularly for commercial therapies where supply chain disruption could impact patient access to life-saving treatments. Cryoport's global network and scale advantages provide another layer of protection. The company has built specialized facilities and partnerships across multiple continents, creating a comprehensive logistics infrastructure that would be expensive and time-consuming for competitors to replicate. The company's CryoPortal platform and condition monitoring systems represent proprietary technology that integrates deeply with customer operations. However, the moat faces several potential threats. Large logistics companies like FedEx, UPS, and DHL have significantly greater resources and could potentially enter the specialized life sciences logistics market if it becomes sufficiently attractive. These companies already have global networks and could leverage their scale to offer competitive pricing. The standardization of cell and gene therapy manufacturing could potentially commoditize some logistics requirements over time. As the industry matures, shipping requirements may become more standardized, reducing the need for highly specialized services. Additionally, some large pharmaceutical companies are developing internal logistics capabilities for their most critical products. Technological disruption represents another risk, as advances in packaging technology, monitoring systems, or even changes in therapy formulations could alter logistics requirements. The company must continuously invest in R&D to maintain its technological edge. Overall, while Cryoport has built meaningful competitive advantages in a specialized niche, the moat's durability depends on the company's ability to maintain its technological leadership and customer relationships as the market evolves and potentially attracts larger, well-resourced competitors.
Risks & safety
Cryoport presents a moderate margin of safety with some concerning financial metrics but strong liquidity position. • Cash and Liquidity: Strong cash position of $36.1 million with current ratio of 5.56, providing substantial near-term financial flexibility. Total current assets of $411.3 million significantly exceed current liabilities of $74.0 million. • Debt and Solvency: Debt-to-equity ratio of 0.61 is manageable but has increased from prior periods. The company is burning cash operationally and had negative free cash flow, though the strong balance sheet provides runway for operations. • Profitability Concerns: Negative EBITDA of -$9.5 million in Q1 2024 and consistently negative operating cash flows indicate the company is not yet profitable at current scale. Management is implementing cost reduction initiatives to reach positive adjusted EBITDA. • Valuation Metrics: Trading at 0.76x book value suggests potential undervaluation, though negative earnings make traditional P/E ratios less meaningful. The company's enterprise value reflects the current unprofitability. • Other Considerations: Revenue guidance maintained at $242-252 million for 2024 suggests management confidence in business trajectory. The company supports 675 clinical trials with expected therapy approvals providing future revenue catalysts, but execution risk remains given current losses and competitive pressures in key markets like China.
Recent development
Over the past few years, Cryoport has executed a comprehensive transformation strategy to position itself as a leading global life sciences logistics platform. The company has made several strategic acquisitions to expand its capabilities and geographic reach, including Cell&Co Bioservices in France, Cell Matters in Belgium, TEC4MED LifeSciences in Germany for AI and monitoring technology, and Bluebird Express to strengthen its US operations. A major strategic initiative has been the development of the IntegriCell platform, designed to standardize apheresis collection processes for cell therapies. This represents Cryoport's expansion upstream into manufacturing support services, with facilities established in Houston and Belgium. The platform is expected to begin generating revenue in 2024, representing a significant expansion beyond traditional logistics services. The company has invested heavily in global infrastructure expansion, opening supply chain centers in Houston, Morris Plains, and establishing its first UK logistics center. These facilities create redundancy and regional capabilities to support the growing global demand for cell and gene therapy logistics. Technology advancement has been another key focus, with the launch of the Cryoport Elite line of shippers, including the UltraCold -80 shipper, and the development of CryoPortal Version 2.0 with enhanced 21 CFR Part 11 compliance. The company has also introduced advanced condition monitoring systems and is exploring opportunities to monetize its data services platform. In response to market challenges, particularly in China where economic conditions have significantly impacted the MVE equipment business, Cryoport has initiated a "China 2025" strategy to manufacture products domestically to meet local "Make in China, Buy in China" requirements. The company has also implemented cost reduction initiatives including workforce reductions and operational restructuring to improve profitability. Strategic partnerships have been established with organizations like the Cell and Gene Therapy Catapult in the UK, NMDP BioTherapies, and Nippon Express in Asia-Pacific to expand market reach and capabilities. These partnerships support the company's goal of building a comprehensive global network for cell and gene therapy logistics.
CYRX company profile · for informational purposes only — not investment advice.
Track CYRX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free